Your browser doesn't support javascript.
loading
Cerebellar Volume and Disease Staging in Parkinson's Disease: An ENIGMA-PD Study.
Kerestes, Rebecca; Laansma, Max A; Owens-Walton, Conor; Perry, Andrew; van Heese, Eva M; Al-Bachari, Sarah; Anderson, Tim J; Assogna, Francesca; Aventurato, Ítalo K; van Balkom, Tim D; Berendse, Henk W; van den Berg, Kevin R E; Betts, Rebecca; Brioschi, Ricardo; Carr, Jonathan; Cendes, Fernando; Clark, Lyles R; Dalrymple-Alford, John C; Dirkx, Michiel F; Druzgal, Jason; Durrant, Helena; Emsley, Hedley C A; Garraux, Gaëtan; Haroon, Hamied A; Helmich, Rick C; van den Heuvel, Odile A; João, Rafael B; Johansson, Martin E; Khachatryan, Samson G; Lochner, Christine; McMillan, Corey T; Melzer, Tracy R; Mosley, Philip E; Newman, Benjamin; Opriessnig, Peter; Parkes, Laura M; Pellicano, Clelia; Piras, Fabrizio; Pitcher, Toni L; Poston, Kathleen L; Rango, Mario; Roos, Annerine; Rummel, Christian; Schmidt, Reinhold; Schwingenschuh, Petra; Silva, Lucas S; Smith, Viktorija; Squarcina, Letizia; Stein, Dan J; Tavadyan, Zaruhi.
Afiliação
  • Kerestes R; Department of Neuroscience, Central Clinical School, Monash University, Melbourne, Victoria, Australia.
  • Laansma MA; Department Anatomy and Neurosciences, Amsterdam UMC, Vrije Universiteit Amsterdam, Amsterdam, The Netherlands.
  • Owens-Walton C; Amsterdam Neuroscience, Neurodegeneration, Amsterdam, The Netherlands.
  • Perry A; Imaging Genetics Center, Mark and Mary Stevens Neuroimaging and Informatics Institute, Keck School of Medicine, University of Southern California, Marina del Rey, California, USA.
  • van Heese EM; Monash Bioinformatics Platform, Monash University, Melbourne, Victoria, Australia.
  • Al-Bachari S; Department Anatomy and Neurosciences, Amsterdam UMC, Vrije Universiteit Amsterdam, Amsterdam, The Netherlands.
  • Anderson TJ; Amsterdam Neuroscience, Neurodegeneration, Amsterdam, The Netherlands.
  • Assogna F; Faculty of Health and Medicine, The University of Lancaster, Lancaster, United Kingdom.
  • Aventurato ÍK; New Zealand Brain Research Institute, Christchurch, New Zealand.
  • van Balkom TD; Neurology Department, Te Whatu Ora - Health New Zealand Waitaha Canterbury, Christchurch, New Zealand.
  • Berendse HW; Laboratory of Neuropsychiatry, IRCCS Santa Lucia Foundation, Rome, Italy.
  • van den Berg KRE; Department of Neurology, University of Campinas - UNICAMP, Campinas, Brazil.
  • Betts R; Brazilian Institute of Neuroscience and Neurotechnology, Campinas, Brazil.
  • Brioschi R; Department Anatomy and Neurosciences, Amsterdam UMC, Vrije Universiteit Amsterdam, Amsterdam, The Netherlands.
  • Carr J; Amsterdam Neuroscience, Neurodegeneration, Amsterdam, The Netherlands.
  • Cendes F; Department Psychiatry, Amsterdam UMC, Vrije Universiteit Amsterdam, Amsterdam, The Netherlands.
  • Clark LR; Department Neurology, Amsterdam UMC, Vrije Universiteit Amsterdam, Amsterdam, The Netherlands.
  • Dalrymple-Alford JC; Department of Neurology and Center of Expertise for Parkinson and Movement Disorders, Donders Institute for Brain, Cognition and Behaviour, Radboud University Medical Centre, Nijmegen, The Netherlands.
  • Dirkx MF; Centre for Cognitive Neuroimaging, Donders Institute for Brain, Cognition and Behaviour, Radboud University Nijmegen, Nijmegen, The Netherlands.
  • Druzgal J; School of Physics and Astronomy, Faculty of Science and Engineering, The University of Manchester, Manchester, United Kingdom.
  • Durrant H; Department of Neurology, University of Campinas - UNICAMP, Campinas, Brazil.
  • Emsley HCA; Division of Neurology, Tygerberg Hospital and Stellenbosch University, Cape Town, South Africa.
  • Garraux G; Department of Neurology, University of Campinas - UNICAMP, Campinas, Brazil.
  • Haroon HA; Brazilian Institute of Neuroscience and Neurotechnology, Campinas, Brazil.
  • Helmich RC; Department of Neurology, University of Pennsylvania Perelman School of Medicine, Philadelphia, Pennsylvania, USA.
  • van den Heuvel OA; New Zealand Brain Research Institute, Christchurch, New Zealand.
  • João RB; Department of Medicine, University of Otago, Christchurch, New Zealand.
  • Johansson ME; School of Psychology, Speech and Hearing, University of Canterbury, Christchurch, New Zealand.
  • Khachatryan SG; Department of Neurology and Center of Expertise for Parkinson and Movement Disorders, Donders Institute for Brain, Cognition and Behaviour, Radboud University Nijmegen Medical Centre, Nijmegen, The Netherlands.
  • Lochner C; Department of Radiology and Medical Imaging, University of Virginia, Charlottesville, Virginia, USA.
  • McMillan CT; School of Physics and Astronomy, Faculty of Science and Engineering, The University of Manchester, Manchester, United Kingdom.
  • Melzer TR; Lancaster Medical School, Lancaster University, Lancaster, United Kingdom.
  • Mosley PE; Division of Neuroscience and Experimental Psychology, Faculty of Biology, Medicine and Health, The University of Manchester, Manchester Academic Health Science Centre, Manchester, United Kingdom.
  • Newman B; GIGA-CRC in vivo imaging, University of Liège, Liège, Belgium.
  • Opriessnig P; MoVeRe group, Department of Neurology, CHU de Liège, Belgium.
  • Parkes LM; Division of Psychology, Communication and Human Neuroscience, Faculty of Biology, Medicine and Health, The University of Manchester, Manchester Academic Health Science Centre, Manchester, United Kingdom.
  • Pellicano C; Department of Neurology and Center of Expertise for Parkinson and Movement Disorders, Donders Institute for Brain, Cognition and Behaviour, Radboud University Medical Centre, Nijmegen, The Netherlands.
  • Piras F; Centre for Cognitive Neuroimaging, Donders Institute for Brain, Cognition and Behaviour, Radboud University Nijmegen, Nijmegen, The Netherlands.
  • Pitcher TL; Department Anatomy and Neurosciences, Amsterdam UMC, Vrije Universiteit Amsterdam, Amsterdam, The Netherlands.
  • Poston KL; Amsterdam Neuroscience, Neurodegeneration, Amsterdam, The Netherlands.
  • Rango M; Department Psychiatry, Amsterdam UMC, Vrije Universiteit Amsterdam, Amsterdam, The Netherlands.
  • Roos A; Department of Neurology, University of Campinas - UNICAMP, Campinas, Brazil.
  • Rummel C; Brazilian Institute of Neuroscience and Neurotechnology, Campinas, Brazil.
  • Schmidt R; Department of Neurology and Center of Expertise for Parkinson and Movement Disorders, Donders Institute for Brain, Cognition and Behaviour, Radboud University Nijmegen Medical Centre, Nijmegen, The Netherlands.
  • Schwingenschuh P; Department of Neurology and Neurosurgery, National Institute of Health, Yerevan, Armenia.
  • Silva LS; Centers for Sleep and Movement Disorders, Somnus Neurology Clinic, Yerevan, Armenia.
  • Smith V; Department of Psychiatry, SA MRC Unit on Risk and Resilience in Mental Disorders, Stellenbosch University, Cape Town, South Africa.
  • Squarcina L; Department of Neurology, University of Pennsylvania Perelman School of Medicine, Philadelphia, Pennsylvania, USA.
  • Stein DJ; New Zealand Brain Research Institute, Christchurch, New Zealand.
  • Tavadyan Z; Department of Medicine, University of Otago, Christchurch, New Zealand.
Mov Disord ; 38(12): 2269-2281, 2023 Dec.
Article em En | MEDLINE | ID: mdl-37964373
ABSTRACT

BACKGROUND:

Increasing evidence points to a pathophysiological role for the cerebellum in Parkinson's disease (PD). However, regional cerebellar changes associated with motor and non-motor functioning remain to be elucidated.

OBJECTIVE:

To quantify cross-sectional regional cerebellar lobule volumes using three dimensional T1-weighted anatomical brain magnetic resonance imaging from the global ENIGMA-PD working group.

METHODS:

Cerebellar parcellation was performed using a deep learning-based approach from 2487 people with PD and 1212 age and sex-matched controls across 22 sites. Linear mixed effects models compared total and regional cerebellar volume in people with PD at each Hoehn and Yahr (HY) disease stage, to an age- and sex- matched control group. Associations with motor symptom severity and Montreal Cognitive Assessment scores were investigated.

RESULTS:

Overall, people with PD had a regionally smaller posterior lobe (dmax = -0.15). HY stage-specific analyses revealed a larger anterior lobule V bilaterally (dmax = 0.28) in people with PD in HY stage 1 compared to controls. In contrast, smaller bilateral lobule VII volume in the posterior lobe was observed in HY stages 3, 4, and 5 (dmax = -0.76), which was incrementally lower with higher disease stage. Within PD, cognitively impaired individuals had lower total cerebellar volume compared to cognitively normal individuals (d = -0.17).

CONCLUSIONS:

We provide evidence of a dissociation between anterior "motor" lobe and posterior "non-motor" lobe cerebellar regions in PD. Whereas less severe stages of the disease are associated with larger motor lobe regions, more severe stages of the disease are marked by smaller non-motor regions. © 2023 The Authors. Movement Disorders published by Wiley Periodicals LLC on behalf of International Parkinson and Movement Disorder Society.
Assuntos
Palavras-chave

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Doença de Parkinson Limite: Humans Idioma: En Ano de publicação: 2023 Tipo de documento: Article

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Doença de Parkinson Limite: Humans Idioma: En Ano de publicação: 2023 Tipo de documento: Article